76.30
price down icon0.16%   -0.05
 
loading
Schlusskurs vom Vortag:
$76.25
Offen:
$76.75
24-Stunden-Volumen:
79,984
Relative Volume:
0.03
Marktkapitalisierung:
$11.64B
Einnahmen:
$4.39B
Nettoeinkommen (Verlust:
$-1.58B
KGV:
-7.6606
EPS:
-9.96
Netto-Cashflow:
$546.00M
1W Leistung:
+6.92%
1M Leistung:
-13.51%
6M Leistung:
-46.16%
1J Leistung:
-38.04%
1-Tages-Spanne:
Value
$75.53
$76.94
1-Wochen-Bereich:
Value
$69.83
$79.37
52-Wochen-Spanne:
Value
$68.70
$156.66

Illumina Inc Stock (ILMN) Company Profile

Name
Firmenname
Illumina Inc
Name
Telefon
(858) 202-4500
Name
Adresse
5200 ILLUMINA WAY, SAN DIEGO, CA
Name
Mitarbeiter
8,970
Name
Twitter
@illumina
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
ILMN's Discussions on Twitter

Vergleichen Sie ILMN mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Diagnostics & Research icon
ILMN
Illumina Inc
75.98 11.64B 4.39B -1.58B 546.00M -9.96
Diagnostics & Research icon
TMO
Thermo Fisher Scientific Inc
421.62 164.88B 42.88B 6.34B 7.27B 16.53
Diagnostics & Research icon
DHR
Danaher Corp
194.06 136.41B 23.88B 3.90B 5.30B 5.28
Diagnostics & Research icon
IDXX
Idexx Laboratories Inc
428.00 32.61B 3.90B 887.87M 798.08M 10.67
Diagnostics & Research icon
A
Agilent Technologies Inc
104.50 29.28B 6.53B 1.26B 1.31B 4.35
Diagnostics & Research icon
IQV
Iqvia Holdings Inc
146.96 26.17B 15.41B 1.37B 2.11B 7.50

Illumina Inc Stock (ILMN) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-04 Bestätigt Citigroup Neutral
2025-02-28 Herabstufung HSBC Securities Buy → Hold
2025-02-10 Herabstufung Barclays Equal Weight → Underweight
2025-02-07 Herabstufung TD Cowen Buy → Hold
2024-12-11 Herabstufung Citigroup Buy → Neutral
2024-11-12 Fortgesetzt Morgan Stanley Equal-Weight
2024-10-17 Hochstufung HSBC Securities Hold → Buy
2024-08-28 Hochstufung Argus Hold → Buy
2024-08-16 Hochstufung Daiwa Securities Neutral → Buy
2024-08-14 Hochstufung Barclays Underweight → Equal Weight
2024-08-14 Hochstufung TD Cowen Hold → Buy
2024-07-10 Hochstufung Citigroup Neutral → Buy
2024-06-03 Fortgesetzt Jefferies Hold
2024-01-16 Herabstufung HSBC Securities Buy → Hold
2024-01-04 Herabstufung TD Cowen Outperform → Market Perform
2023-12-18 Hochstufung Scotiabank Sector Perform → Sector Outperform
2023-12-15 Hochstufung Bernstein Underperform → Mkt Perform
2023-12-14 Eingeleitet Guggenheim Buy
2023-12-14 Eingeleitet Stephens Overweight
2023-12-13 Eingeleitet Wolfe Research Outperform
2023-12-12 Herabstufung BofA Securities Neutral → Underperform
2023-12-11 Hochstufung Citigroup Sell → Neutral
2023-11-10 Herabstufung Canaccord Genuity Buy → Hold
2023-09-28 Eingeleitet Bernstein Underperform
2023-07-05 Fortgesetzt JP Morgan Neutral
2023-01-25 Herabstufung Argus Buy → Hold
2023-01-05 Eingeleitet Scotiabank Sector Perform
2022-12-12 Herabstufung Citigroup Neutral → Sell
2022-12-07 Eingeleitet RBC Capital Mkts Outperform
2022-10-04 Hochstufung SVB Leerink Mkt Perform → Outperform
2022-09-28 Hochstufung Evercore ISI In-line → Outperform
2022-08-25 Eingeleitet Credit Suisse Neutral
2022-07-13 Herabstufung Barclays Equal Weight → Underweight
2022-01-18 Hochstufung Stifel Hold → Buy
2022-01-11 Hochstufung Barclays Underweight → Equal Weight
2022-01-07 Hochstufung BofA Securities Underperform → Neutral
2022-01-06 Fortgesetzt Morgan Stanley Equal-Weight
2022-01-06 Fortgesetzt Piper Sandler Overweight
2021-10-15 Fortgesetzt Cowen Outperform
2021-08-19 Herabstufung SVB Leerink Outperform → Mkt Perform
2021-06-01 Hochstufung Evercore ISI Underperform → In-line
2021-03-31 Herabstufung Atlantic Equities Overweight → Neutral
2021-03-31 Hochstufung Canaccord Genuity Hold → Buy
2021-03-03 Eingeleitet Barclays Underweight
2020-12-22 Hochstufung Piper Sandler Neutral → Overweight
2020-12-17 Hochstufung BTIG Research Neutral → Buy
2020-10-13 Herabstufung Guggenheim Buy → Neutral
2020-09-30 Eingeleitet Atlantic Equities Overweight
2020-09-29 Herabstufung Wolfe Research Outperform → Peer Perform
2020-09-22 Herabstufung Stifel Buy → Hold
2020-09-22 Herabstufung UBS Buy → Neutral
2020-09-21 Hochstufung Guggenheim Neutral → Buy
2020-09-21 Herabstufung JP Morgan Overweight → Neutral
2020-09-09 Eingeleitet Morgan Stanley Equal-Weight
2020-08-07 Herabstufung Evercore ISI In-line → Underperform
2020-08-07 Herabstufung Piper Sandler Overweight → Neutral
2020-07-07 Herabstufung Guggenheim Buy → Neutral
2020-04-24 Herabstufung Citigroup Buy → Neutral
2020-04-21 Herabstufung Robert W. Baird Outperform → Neutral
2020-01-08 Eingeleitet Wells Fargo Underweight
2020-01-07 Eingeleitet Citigroup Buy
2020-01-02 Herabstufung Evercore ISI Outperform → In-line
2019-11-15 Eingeleitet Stifel Buy
2019-10-25 Eingeleitet Guggenheim Buy
Alle ansehen

Illumina Inc Aktie (ILMN) Neueste Nachrichten

pulisher
07:57 AM

Should You Hold Illumina (ILMN)? - Yahoo Finance

07:57 AM
pulisher
Apr 23, 2025

Veraxa makes a SPAC deal; Illumina discloses layoffs - Endpoints News

Apr 23, 2025
pulisher
Apr 22, 2025

Resmed Taps Illumina Exec for Chief Investor Relations Officer Role - Medical Product Outsourcing

Apr 22, 2025
pulisher
Apr 22, 2025

Microarray Market Projected To Witness Massive Growth, 2025-2032 | Thermo Fisher Scientific Inc.,Illumina Inc. - openPR.com

Apr 22, 2025
pulisher
Apr 22, 2025

DNA Microarray Technology Market: Innovations & Opportunities - openPR.com

Apr 22, 2025
pulisher
Apr 22, 2025

Cancer Biopsy Market Detailed In New Research Report 2025 | - openPR.com

Apr 22, 2025
pulisher
Apr 22, 2025

Genomic Cancer Testing Market Overall Study Report 2025-2032 | - openPR.com

Apr 22, 2025
pulisher
Apr 21, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 21, 2025
pulisher
Apr 21, 2025

Thomas Kean Jr purchases shares in Illumina and nVent Electric - Investing.com Australia

Apr 21, 2025
pulisher
Apr 21, 2025

Resmed Names Salli Schwartz as Chief Investor Relations Officer - The Manila Times

Apr 21, 2025
pulisher
Apr 21, 2025

Resmed Names Salli Schwartz as Chief Investor Relations Officer - GlobeNewswire Inc.

Apr 21, 2025
pulisher
Apr 21, 2025

Illumina, Inc. (ILMN): Among Recent Activist Investor Campaigns - Insider Monkey

Apr 21, 2025
pulisher
Apr 21, 2025

Controlling Genes Market Detailed in New Research Report By 2032 - openPR.com

Apr 21, 2025
pulisher
Apr 18, 2025

Illumina (ILMN) Receives a Buy from Leerink Partners - The Globe and Mail

Apr 18, 2025
pulisher
Apr 18, 2025

Illumina, Tempus AI partner to drive genomic testing beyond cancer - MedTech Dive

Apr 18, 2025
pulisher
Apr 18, 2025

Q4 Rundown: Illumina (NASDAQ:ILMN) Vs Other Life Sciences Tools & Services Stocks - Yahoo Finance

Apr 18, 2025
pulisher
Apr 17, 2025

DNA Methylation Market Deep Research Report with Forecast by 2032 | Illumina, Inc.,Thermo Fisher Scientific - openPR.com

Apr 17, 2025
pulisher
Apr 17, 2025

RNA Sequencing Market Size, Share, Outlook, Industry Analysis, - openPR.com

Apr 17, 2025
pulisher
Apr 17, 2025

MicroRNA Market Size, Share, Trends, Opportunities, - openPR.com

Apr 17, 2025
pulisher
Apr 16, 2025

AI in Omics Studies Market Overall Study Report 2025-2032 | Thermo Fisher Scientific, Agilent Technologies, Illumina - openPR.com

Apr 16, 2025
pulisher
Apr 15, 2025

Illumina, Tempus AI To Collaborate To Accelerate Genomic AI Innovation - Nasdaq

Apr 15, 2025
pulisher
Apr 15, 2025

Illumina and Tempus join forces to expand genomic testing By Investing.com - Investing.com India

Apr 15, 2025
pulisher
Apr 15, 2025

Illumina, Tempus AI Collaborating to Accelerate Clinical Use of Sequencing Tests - marketscreener.com

Apr 15, 2025
pulisher
Apr 15, 2025

Illumina And Tempus Partner To Drive The Future Of Precision Medicine Through Genomic Ai Innovation - MarketScreener

Apr 15, 2025
pulisher
Apr 15, 2025

Illumina and Tempus join forces to expand genomic testing - Investing.com

Apr 15, 2025
pulisher
Apr 15, 2025

Illumina and Tempus partner to drive the future of precision medicine through genomic AI innovation - PR Newswire

Apr 15, 2025
pulisher
Apr 14, 2025

BofA Securities Cuts Price Target on Illumina to $75 From $90, Keeps Underperform Rating - MarketScreener

Apr 14, 2025
pulisher
Apr 13, 2025

SHAREHOLDER ALERT: Levi & Korsinsky Notifies Shareholders of Illumina, Inc.(ILMN) of a Class Action Lawsuit and an Upcoming Deadline - ACCESS Newswire

Apr 13, 2025
pulisher
Apr 13, 2025

Illumina (NASDAQ:ILMN) Price Target Cut to $112.00 by Analysts at Royal Bank of Canada - MarketBeat

Apr 13, 2025
pulisher
Apr 12, 2025

Illumina : Welcomes Alex Aravanis as Chief Technology Officer and Appoints Mostafa Ronaghi to Lead Entrepreneurial Development - MarketScreener

Apr 12, 2025
pulisher
Apr 11, 2025

Personalized Medicine Market Forecast Report and Company Analysis 2025-2033 Featuring Abbott, GE, Aadi Bioscience, Illumina, QIAGEN, Eli Lilly and Co, Takeda, AbbVie, F. Hoffmann-La RocheResearchAndMarkets.com | FinancialContent - FinancialContent

Apr 11, 2025
pulisher
Apr 10, 2025

Illumina To Announce First Quarter 2025 Financial Results On Thursday, May 8, 2025 - MarketScreener

Apr 10, 2025
pulisher
Apr 10, 2025

Shareholders in Illumina (NASDAQ:ILMN) have lost 77%, as stock drops 6.8% this past week - simplywall.st

Apr 10, 2025
pulisher
Apr 10, 2025

Illumina to Announce First Quarter 2025 Financial Results on Thursday, May 8, 2025 - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Single-cell Omics Emerging Technologies and Markets Report 2025: 10x Genomics, Thermo Fisher & Illumina Lead $9.1 Billion Single-cell Omics Market by 2029 - Yahoo Finance

Apr 10, 2025
pulisher
Apr 10, 2025

Cancer Profiling Market Positioned for Accelerated Growth with - openPR.com

Apr 10, 2025
pulisher
Apr 10, 2025

Illumina (ILMN) Receives a Sell from Barclays - The Globe and Mail

Apr 10, 2025
pulisher
Apr 09, 2025

Corvex’s Meister joins the board at Illumina. Here’s how he can create value for shareholders - MSN

Apr 09, 2025
pulisher
Apr 09, 2025

Genotyping Assay Market Surges to USD 37.1 Billion by 2029: - openPR.com

Apr 09, 2025
pulisher
Apr 09, 2025

Biotechnology company Illumina names Julie Hiner as comms head - Medical Marketing and Media

Apr 09, 2025
pulisher
Apr 09, 2025

PacBio to cut jobs, lower spending over NIH funding cuts and tariffs - MarketScreener

Apr 09, 2025
pulisher
Apr 09, 2025

DNA Data Storage Market to See Booming Growth 2025-2032 | Illumina, Inc.,Microsoft,Iridia, Inc.,Twist Bioscience - openPR.com

Apr 09, 2025
pulisher
Apr 08, 2025

DNA Sequencing Technologies Market Deep Research Report with - openPR.com

Apr 08, 2025
pulisher
Apr 08, 2025

Admera Health uses the NovaSeq X Plus to expand capabilities - Illumina

Apr 08, 2025
pulisher
Apr 08, 2025

RBC Cuts Price Target on Illumina to $112 From $128, Keeps Outperform Rating - MarketScreener

Apr 08, 2025
pulisher
Apr 08, 2025

Minimal Residual Disease Testing Market Forecast Report, 2025-2030 - GlobeNewswire Inc.

Apr 08, 2025
pulisher
Apr 08, 2025

Where are the Opportunities in (ILMN) - news.stocktradersdaily.com

Apr 08, 2025
pulisher
Apr 07, 2025

Deep Dive Into Illumina Stock: Analyst Perspectives (14 Ratings) - Benzinga

Apr 07, 2025
pulisher
Apr 07, 2025

Apple To $250? Here Are 10 Top Analyst Forecasts For Monday - Benzinga

Apr 07, 2025
pulisher
Apr 07, 2025

How Do Investors Really Feel About Illumina? - Benzinga

Apr 07, 2025
pulisher
Apr 07, 2025

California Public Employees Retirement System Reduces Position in Illumina, Inc. (NASDAQ:ILMN) - MarketBeat

Apr 07, 2025

Finanzdaten der Illumina Inc-Aktie (ILMN)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
diagnostics_research DGX
$173.97
price down icon 0.05%
diagnostics_research LH
$222.92
price down icon 0.56%
diagnostics_research WAT
$328.78
price down icon 1.78%
$149.19
price up icon 3.02%
diagnostics_research MTD
$1,044.96
price up icon 4.17%
diagnostics_research IQV
$146.54
price up icon 2.44%
Kapitalisierung:     |  Volumen (24h):